Janelsins et al. [29] | Longitudinal | BC CH+ (n = 580) | HC (n = 363) | 10-point Likert scale; modified MD Anderson Symptom Inventory [31] | Difference in mean score(SE) trajectory between exposure and control: - From pre-treatment to post-treatment: 1.15 (0.14) (95% CI 0.88 - 1.42; p < 0.001) - From post-treatment to 6-month follow-up: 0.86 (0.14) (95% CI 0.58 - 1.13; p < 0.001) | Difference in mean score(SE) trajectory between exposure and control: - From pre-treatment to post-treatment: 0.99 (0.15) (95% CI 0.7 - 1.28; p < 0.001) - From post-treatment to 6 -month follow-up: 0.52 (0.15) (95% CI 0.22 - 0.81; p < 0.001) | Difference in mean score(SE) trajectory between exposure and control: - From pre-treatment to post-treatment: 1.24 (0.17) (95% CI 0.92 - 1.57; p < 0.001) - From post-treatment to 6-month follow-up: 0.84 (0.17) (95% CI 0.50 - 1.17; p < 0.001) | n/a |
Janelsins et al. [30] | Longitudinal | BC CH+ (n = 581) | HC (n = 364) | FACT-COG | n/a | n/a | n/a | Change in mean (SD) score from pre-treatment to post-treatment: - CH+: -15.9 (30.86) (p < 0.001) - CH−: +1.4 (16.38) (p = 0.122) Change in mean (SD) score from pre-treatment to 6 – month follow-up: - CH+: −10.4 (31.41) (p < 0.001) - CH−: +1.5 (16.31) (p = 0.1) |
Kohli et al. [32] | Longitudinal | Various Solid Malignancies CH+; (n = 595) | n/a* | 11 – point Likert scale; modified MD Anderson Symptom Inventory [7] | Baseline = 54.5% During treatment = 81.8% 6 months post-treatment = 76.4% | Baseline = 55.9% During treatment = 85.9% 6 months post-treatment = 68.6% | n/a | n/a |
Tager et al. [33] | Longitudinal | BC; CH+ (n = 61) | BC; CH− (n = 31) | 5-Point Likert Scale | 27% vs 32% before treatment; 43% vs 35% at 6 months post-treatment; 46% vs 31% at 6 months follow-up | n/a | n/a | n/a |